Home > Insider Trading > Filing (0000899243-18-008309)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1679082	Myovant Sciences Ltd.	MYOV	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1395064	Takeda Pharmaceutical Co Ltd	12-10, Nihonbashi 2-Chome, Chuo-Ku Tokyo M0 103-8668	No	No	Yes	No
1688140	Ag International Pharmaceuticals Takeda	Thurgauerstrasse 130, 8152 Glattpark-Opfikon Zurich V8 8152	No	No	Yes	No
1716226	A/S Pharma Takeda	Dybendal Alle 10,2630 Taastrup G7	No	No	Yes	No
1716379	B.v. Holdings Europe Takeda	Jupiterstraat 250, 2132 Hk Hoofddorp P7	No	No	Yes	No
1716380	A/S Takeda	Dybendal Alle 10, 2630 Taastrup G7	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-03-19	7,420,625	$18.67	0	No	4	S	Direct
Common Stock	Acquisiton	2018-03-19	7,420,625	$18.67	7,420,625	No	4	P	Indirect	By MillenniumPharmaceuticals, Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	P	Indirect	By MillenniumPharmaceuticals, Inc.

Footnotes

On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC.
(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.